The short version
- Amplifon said its third-quarter revenue was €575 million, with 3.6% organic growth and profit up nearly 22%.
- In the Americas, people paying for hearing care themselves kept buying while insurance-funded sales were weak.
- Its shareholders approved 56 million new shares for its roughly $2.5 billion purchase of GN Hearing, which is expected to close by the end of 2026.
Amplifon, the Italian hearing-care chain, said its third-quarter revenue rose 2.1% to €575 million (about $621 million), or 3.6% after stripping out acquisitions and currency. Asia Pacific grew 4.2%, Europe, the Middle East and Africa 3.5%, and the Americas 3.3%. In the US, private-pay demand was strong and insurance-funded demand was weak. Adjusted operating profit rose nearly 22% in the quarter after the company closed more than 230 clinics, ended a US managed-care agreement and sold businesses in the UK and India.
On October 29 shareholders approved the 56 million new shares that make up the stock part of Amplifon’s roughly $2.5 billion purchase of GN Hearing, the maker of ReSound, Beltone and Interton hearing aids. Closing is expected by the end of 2026, pending regulators. The deal would put a hearing-aid maker inside a clinic chain.
These are the company’s own figures, reported by a trade outlet. Earlier this month Demant reported hearing aid sales up 17%. Amplifon expects organic growth above 3% for the year.
